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Sev eral types of gen er a tors have been de vel oped for the pro duc tion of 99mTc. Due to its
excelent per for mances, the chro mato graphic type, based on the fis sion-pro duced
99Mo sorbed in alu mina, is pre dom i nant. Tech ne tium-99m is ob tained in the form of
so dium pertechnetate-99mTc. How ever, due to the known dis ad van tages of the pro -
duc tion of (n, f)99Mo, at tempts are made to avoid ura nium fis sion. The tech nol o gies
based on (n, g)99Mo (sub li ma tion, ex trac tion, gel) are, with the ex cep tion of the gel
gen er a tor, of lim ited im por tance. Cer tain nu clear re ac tions in cy clo trons can pro duce
99Mo (or di rectly 99mTc) but the ob tained re sults are still not sat is fy ing. Tech ne -
tium-99m is used in the form of radiopharmaceuticals which are pre pared by ad di tion
of 99mTc-eluate to the in ac tive com po nents com prised in the “cold” kits. The chro -
mato graphic (n, f)99Mo/99mTc gen er a tor and sev eral 99mTc-radiopharmaceuticals have
been de vel oped and are reg u larly pro duced in the Vin~a In sti tute of Nu clear Sci ences
(Lab o ra tory for Ra dio iso topes).
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technetium-99m-radiopharmaceuticals
INTRODUCTION
Nu clear med i cine is a med i cal mo dal ity which
uses nu clear prop er ties of radionuclides to di ag nose dis -
eases.The best suited ones are g-emit ters. It is es sen tial
that a given radionuclide is con cen trated in the ad e quate
area in the or gan ism. Usu ally, this is achieved by at tach -
ing it to a chem i cal which is se lec tively sorbed by spe -
cific or gans or tis sues. Af ter a cer tain time af ter its in tro -
duc tion into the body, it is ac cu mu lated in the de sired
spot. The emit ted ra di a tion pen e trates the tis sues and is
fi nally de tected by an ex ter nal count ing de vice. The ob -
tained scintigram pro vides the in for ma tion needed for di -
ag nos tics (the size, shape, func tion of the given or gan).
The chem i cal with the at tached radionuclide is usu ally
de noted as a radiopharmaceutical.
Be side on phys i cal prop er ties (the type and en -
ergy of ra di a tion emit ted, half life), the rou tine ap pli -
ca tion of a given radionuclide de pends also on its
avail abil ity in suf fi cient ac tiv i ties, qual ity and price.
The de vel op ment of ad e quate chem is try is needed for
the pro duc tion of radiopharmaceuticals. An elab o -
rated pro duc tion pro ce dure on the reg u lar ba sis should 
be es tab lished, in clud ing the nec es sary fa cil i ties. The
shorter-lived radionuclides should be avail able ei ther
from gen er a tors or from an ef fi cient cen tral dis tri bu -
tion sup ply [1-3].
For years, the most of ten used radionuclide in di -
ag nos tics has been 99mTc. Ex cel lent phys i cal and
chem i cal prop er ties made it ap pli ca ble in a large va ri -
ety of in di ca tions. Tech ne tium-99m ful fils all other
cri te ria re quired for a broad use: re li able pro duc tion at
the ap pro pri ate price, easy and reg u lar avail abil ity, and 
known chem is try. The chro mato graphic 99Mo/99mTc
gen er a tors based on the par ent 99Mo ob tained from
ura nium fis sion have be come the com mon and very re -
li able source of large ac tiv i ties of 99mTc of high qual ity
meet ing all cri te ria pre scribed by Phar ma co poeia.
Ura nium fis sion en sures large ac tiv i ties of 99Mo
needed for the reg u lar gen er a tor pro duc tion.
The pa per pres ents a short re view cov er ing some 
im por tant as pects of the pro duc tion of 99mTc and its
par ent radionuclide 99Mo. The radiopharmaceuticals
la beled with 99mTc are widely in ves ti gated. The main
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prep a ra tions, in di ca tions for their use and the rec om -
mended 99mTc-ac tiv i ties are given.
PRO DUC TION OF MO LYB DE NUM-99
Mo lyb de num-99 is rou tinely pro duced in nu -
clear re ac tors. Two nu clear re ac tions are em ployed.
The first one is the di rect neu tron ac ti va tion of the sta -
ble 98Mo which gives the so-called (n, g)99Mo. The
sec ond route is ura nium fis sion in duced by neu trons.
By sep a ra tion from other fis sion prod ucts, mo lyb de -
num-99, usu ally de noted as (n, f)99Mo, is ob tained [4].
The ad van tage of the pro duc tion of (n, g)99Mo is
that it is rel a tively sim ple and cheap. Large quan ti ties
of the tar get ma te rial (mo lyb de num tri ox ide, with
98Mo in nat u ral abun dance or en riched in 98Mo), can
be eas ily ir ra di ated with the min i mal need for the
post-ir ra di a tion pro cess ing. Only small quan ti ties of
low-ac tiv ity ra dio ac tive waste are pro duced. By the
proper choice of the tar get, the con tent of the
radionuclidic im pu ri ties can be re duced to min i mum.
The main dis ad van tage is the low spe cific ac tiv ity of
99Mo (less than 400 GBq/g Mo). Also, high flux nu -
clear re ac tors are not al ways at the dis posal.
The neu tron-in duced fis sion of 235U is cur rently
the main source of com mer cial (n, f)99Mo. The tar get
con tains 235U in nat u ral abun dance (0.7%) or en riched
235U up to al most 100%. The fis sion yield is about 6%.
The ad van tages of this tech nol ogy are high ac tiv i ties
and very high spe cific ac tiv i ties of the pro duced 99Mo
[5]. How ever, there are some prin ci pal dis ad van tages
that have to be care fully con sid ered. They are: eco -
nom i cal (high cap i tal and run ning costs), com plex
sep a ra tion of 99Mo in clud ing the re cov ery of the
non-re acted ura nium, eco log i cal (the gen er a tion of
large quan ti ties of high-ac tiv ity waste), and po lit i cal
(tar get ma te rial has the po ten tial for the clan des tine
use in nu clear weap ons).
Cur rently, over 95% of 99Mo is pro duced by us -
ing highly en riched ura nium (HEU) tar gets. This pro -
duc tion is car ried out in a lim ited num ber of in dus trial
com pa nies and na tional cen ters. They, col lec tively, are 
able to cover the world’s de mand for 99Mo, but any
dis tur bance in the pro duc tion could have high neg a -
tive im pact on the rou tine sup ply of med i cal cen ters
with 99mTc.
Sev eral at tempts have been made to avoid fis -
sion. At trac tive and com pet i tive al ter na tive to re ac tors 
may be cy clo trons. Sev eral nu clear re ac tions con sid -
ered for an even tual pro duc tion of 99Mo (or di rectly
99mTc) are listed in tab. 1.
The pro duc tion of 99Mo by the nu clear re ac tion
100Mo(g, n)99Mo fol lowed by the sep a ra tion of 99mTc
by sub li ma tion is prom is ing [6]. The re ac tion 100Mo(p, 
2n)99mTc pro ceeds with an ac cept able yield un der con -
di tion that highly en riched tar get ma te rial is used [7].
How ever, both nu clear re ac tions pro duce ac tiv i ties
which are too low to cover the needs. There fore, it
could be con cluded that the ex ist ing op tions still can
not com pete with the ura nium fis sion.
TECH NE TIUM-99m 
AND TECH NE TIUM-99m
RADIOPHARMACEUTICALS
Tech ne tium-99m is the main radionuclide for in
vivo di ag nos tics in nu clear med i cine. Its draw back,
how ever, is a rel a tively short half-life of six hours, so
that dis tant us ers can not be sup plied with out heavy
losses in ac tiv ity. This lo gis tic prob lem is solved with
the de vel op ment of 99Mo/99mTc gen er a tors. The prin -
ci ple of the gen er a tor is based on the ra dio ac tive par ent 
99Mo (T1/2 = 66 hours), which de cays to the daugh ter
radionuclide 99mTc (T1/2 = 6 hours). So, in stead of the
short-lived 99mTc, the lon ger-lived 99Mo, bound to an
ap pro pri ate ma trix, is shipped and 99mTc is sep a rated
by the end user. Mo lyb de num-99 then, by de cay, gen -
er ates a new sup ply of the daugh ter so that the sep a ra -
tion can be re peated. The gen er a tors are usu ally cal i -
brated a few days in ad vance so that they can be
trans ported to places very dis tant from the pro duc tion
site. Nor mally, a gen er a tor is used for 14 days af ter cal -
i bra tion. Af ter that, its ac tiv ity is al ready too low and it
is shipped back to the pro ducer where it is dis posed of.
Ta ble 2 re veals the main gen er a tor types in de -
pend ence on the tech nol ogy of the sep a ra tion of 99mTc
from 99Mo.
The best one is the chro mato graphic (n,
f)99Mo/99mTc gen er a tor. Fis sion-pro duced 99Mo can be,
due to its very high spe cific ac tiv ity, sorbed in a small
vol ume of sorbent (most of ten alu mina). There fore, the
col umn usu ally con tains up to 1 g of alu mina only. For
the elu tion, the small vol umes of eluence are needed,
which re sults in a high spe cific ac tiv ity prod uct. The gen -
er a tor is sim ple, por ta ble and easy to use.
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The rea son why (n, g)99Mo can not be used for the
pro duc tion of the chro mato graphic gen er a tors is its low
spe cific ac tiv ity. The sorp tion ca pac ity of alu mina for
molybdate an ions is only about 0.2 wt.%. So, for the
sorp tion of higher ac tiv i ties of (n, g)99Mo large col umns 
are needed (about 20 g of alu mina). High elu tion vol -
umes re sult in low spe cific ac tiv ity 99mTc. Even by us -
ing tar gets highly en riched in 98Mo, the ob tained 99Mo
would en able the pro duc tion of the chro mato graphic
gen er a tors of the ac tiv i ties of up to about 2 GBq of
99mTc. For the mod ern nu clear med i cine this is in suf fi -
cient. For com par i son, most of ten used are the gen er a -
tors of the ac tiv i ties be tween 12-20 GBq. For some spe -
cific ap pli ca tions, ac tiv i ties of up to 37 GBq are needed. 
This can be achieved only by us ing (n, f)99Mo.
For the sep a ra tion of 99mTc from (n, g)99Mo other 
meth ods, rather than the chro ma tog ra phy, have been
used (tab. 2). The dif fer ences in the volatilities of ox -
ides of 99mTc and 99Mo are ex ploited in the sub li ma tion 
gen er a tors. Tech ne tium-99m can also be iso lated by
sol vent ex trac tion, mainly by us ing methyl ethyl
ketone (ex trac tion gen er a tors). The gel gen er a tor
com bines the ex cel lent per for mances of the chro mato -
graphic gen er a tor and the use of (n, g)99Mo. In stead
with alu mina, the gen er a tor col umn is filled with the
ir ra di ated pow der of zir co nium or ti ta nium molybdate. 
Thus, the con tent of mo lyb de num in the col umn is
raised up to 40 wt.%, thus pro vid ing higher ac tiv i ties
of 99mTc. Fur ther data on the per for mances of these
gen er a tors can be found in lit er a ture [8].
The com mon com ment to these, some times
named the al ter na tive gen er a tor tech nol o gies, can be
sum ma rized as fol lows. Ex trac tion and sub li ma tion
gen er a tors are com plex de vices in which the qual ity
of 99mTc de pends also on the skill of the op er a tor.
Prob a bly the best per spec tive is of fered by the gel
gen er a tor. How ever, all three types, with out some es -
sen tial in no va tion, can not com pete with the chro -
mato graphic gen er a tor based on (n, f)99Mo. It should
be men tioned that these types of gen er a tors have been 
de vel oped and used mainly in the coun tries which,
due to the eco nom i cal or geo graph ical rea sons, do not 
have ac cess to (n, f)99Mo.
The chro mato graphic (n, f)99Mo/99mTc gen er a -
tors have been de vel oped in sev eral coun tries. A fea -
ture com mon to them all is a glass or plas tic col umn
filled with alu mina onto which (n, f)99Mo is sorbed.
Tech ne tium-99m is eluted by suck ing the eluence sa -
line (0.9% NaCl) through the col umn by vac uum. The
pre dom i nant type is the “dry” type in which the col -
umn is dry be tween two suc ces sive elutions. In the
“wet” type the col umn re mains filed with sa line. The
col umn is in cor po rated in a closed elu tion sys tem, thus 
min i miz ing the risk of mi cro bial con tam i na tion and
sit u ated in a pro tec tive lead shield ing. The whole as -
sem bly is in a plas tic con tainer.
Many coun tries run the gen er a tor pro duc tion by
us ing their own tech nol ogy and the im ported (n, f)99Mo,
thus avoid ing the ex pen sive plants for the ir ra di a tion and
sep a ra tion of (n, f)99Mo. This so lu tion has also been ap -
plied in Ser bia. Now a days, only a few sup pli ers of fis -
sion 99Mo in the world ex ist.
The de vel op ment of the chro mato graphic (n,
f)99Mo/99mTc gen er a tor in the Vin~a In sti tute of
Nu clear Sci ences, Lab o ra tory for Ra dio iso topes,
started more than thirty years ago. It was first re -
ported in 1982 [9] and the first pa per ap peared in
1983 [10]. The plas tic col umn con tains two lay ers:
pure alu mina cov ered by alu mina mod i fied by the
ad di tion of di va lent cop per in which (n, f)99Mo is
sorbed. The elu tion is car ried out by pass ing
home-made sa line (0.9% NaCl) through the col -
umn by vac uum. Af ter elu tion, the col umn is ad di -
tion ally dried (the “dry” type of the gen er a tor). The 
fast and sim ple elu tion pro ce dure, car ried out at
room tem per a ture, is com pleted in less than a min -
ute. Af ter the con nec tion of the vac uum vial, the
pres ence of the op er a tor is not even nec es sary. The
gen er a tor col umn is placed in the pro tec tive lead
con tainer (d  = 41 mm Pb). The tech nol ogy has been 
de vel oped in the Lab o ra tory for Ra dio iso topes and
the only im ported com po nent is (n, f)99Mo. The
rou tine large scale pro duc tion started in 1982 [11].
The de vel op ment and the reg u lar gen er a tor pro -
duc tion in the Lab o ra tory have been ac com pa nied by
the in ves ti ga tions of sev eral as pects of the gen er a tor
sys tem. The sum mary of the re sults is re viewed in ref.
                   Ta ble 2. Meth ods of sep a ra tion of 99mTc from 99Mo, char ac ter is tics of the gen er a tors
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Gel (n, g) 80-95 Simple, portable Yes
[12]. One of the most im por tant is the main te nance of
the high and sta ble 99mTc elu tion yield. The cause of
low yield, i. e., the re ten tion of 99mTc on the col umn,
was found to be the re duc tion of heptavalent tech ne -
tium by hy drated elec trons formed by radiolysis of wa -
ter. The rem edy ap plied was the in tro duc tion of di va -
lent cop per as the rad i cal scav en ger into the col umn
[12, 13]. An im por tant fea ture is the radionuclidic pu -
rity of 99mTc eluates as well. Sev eral ra dio iso topes
(103Ru, 106Ru, 125Sb, 131I), orig i nat ing from (n, f)99Mo, 
were de tected [14]. How ever, the pre scribed cri te rion
of the radionuclidic pu rity is ful filled in all cases. With
re gards to the safe stor age of the spent gen er a tors, the
main long-lived con tam i nants in the col umns were de -
ter mined [15].
Tech ne tium-99m in the gen er a tor eluate is in
the form of 99mTc-pertechnetate (99mTcO4–). The
eluate is the ster ile, py ro gen-free and iso tonic
radiopharmaceucal which can be used, for ex am ple,
for brain im ag ing. How ever, 99mTc is mainly used for
la bel ing com pounds for which it has been es tab lished 
that they per form the af fin ity to ward cer tain or gans or 
tis sues. These radiopharmaceuticals are most of ten
for mu lated in the form of so called “cold” (tech ne -
tium-99m-free) kits. The in ac tive com po nents of a
prep a ra tion are in lyophilized form con tained in a
glass vial usu ally in vac uum or in an in ert at mo -
sphere. To such a pre-ster ile and val i dated com mer -
cial kit, the user should only add a cer tain vol ume of
99mTc eluate con tain ing the needed 99mTc ac tiv ity.
This sim ple “shake, mix or even heat” radiopharma-
ceutical prep a ra tion is per formed in the “hot” lab o ra -
to ries in the nu clear med i cal cen ters.The “cold” kits,
de signed to have a long-term shelf-life, can be trans -
ported at the room tem per a ture and then stored by the
user in a re frig er a tor to en sure their sta bil ity.
Re search in the field of radiochemistry has been
car ried out in the Lab o ra tory for Ra dio iso topes for sev -
eral de cades [16]. The ob tained re sults to gether with the 
in ves ti ga tions in chem is try, phys i cal chem is try, bio -
chem is try, and radiopharmacy have formed the ba sis
for the pro duc tion of radionuclides (32P, 35S, 51Cr, 131I,
198Au, etc.) and radiopharmaceuticals for med i cal use
[17]. In the early sev en ties of the past cen tury, 99mTc and 
its com plex com pounds pre vailed in med i cine. A large
num ber of 99mTc-radiopharmaceuticals were in ves ti -
gated and de vel oped in the Lab o ra tory for the use in di -
ag nos tic in nu clear med i cine. The com plex re search in
phys i cal, an a lyt i cal and co or di na tion chem is try of tech -
ne tium re sulted also in a num ber of pa pers. The re view
of the re sults on 99mTc in the first two de cades is given in 
the lit er a ture [18, 19]. The in ves ti ga tions cov ered sev -
eral top ics. For ex am ple, it is im por tant to es tab lish the
fac tors which in flu ence the con di tions of the com plex
for ma tion, af fect radiochemical pu rity of the prod uct,
etc. [20-25]. The sta bil ity of the “cold” prep a ra tion, the
ef fect of some chem i cal ad di tives, like ascor bic or
gentisic acid [26, 27], etc., is also of in ter est. The com -
pre hen sive sur vey of tech ne tium com plexes, their
struc ture, modes of prep a ra tion, etc., can be found in
ref. [28].
Ta ble 3 pres ents a list of 99mTc radiopharmace-
uticals, in di ca tions for their use and the rec om mended
99mTc ac tiv i ties [3, 12, 29].
To gether with the de vel op ment of pro duc tion of
radionuclides and radiopharmaceuticals, the com pre -
hen sive meth od ol ogy of phys i cal, chem i cal, and phar -
ma ceu ti cal con trol pro ce dures should also be es tab -
lished. Be side the stan dard con trols of ra dio ac tive
sub stances, sev eral spe cific reg u la tions for the
radiopharmaceuticals are in tro duced as these prep a ra -
tions are used in med i cine in vivo and are con sid ered as 
drugs. They are sub jected to the law reg u la tions and to
the re quire ments of Phar ma co poeia. The qual ity con -
trol tests in clude the de ter mi na tion of: radiochemical
pu rity checked by dif fer ent chro mato graphic meth ods, 
radionuclidic pu rity checked by g-spec trom e try, bi o -
logic se lec tiv ity checked by the as sess ment of
biodistribution in ex per i men tal an i mals as well as ste -
ril ity and apyrogenicity checked by microbiologic
meth ods. Chem i cal pu rity tests and the de ter mi na tion
of pH and isotonicity with hu man blood are also pre -
scribed.
The Lab o ra tory for Ra dio iso topes or ga nizes the
rou tine qual ity con trol, both for 99mTc eluates and
99mTc-radiopharmaceuticals. All the tests are per -
formed ac cord ing to Phar ma co poeia [30].
The Lab o ra tory is ac cred ited for the in ves ti ga -
tions of radiopharmaceuticals for in vivo and in vi tro
ap pli ca tions and par tic u larly for 99Mo/99mTc gen er a -
tors and 99mTc eluates.
CON CLU SIONS
Tech ne tium-99m has very suit able phys i cal
prop er ties for in vivo di ag nos tics in nu clear med i cine.
Al most pure g-ra di a tion, with the en ergy of 140 keV is
con ve nient for the com monly used de tec tion equip -
ment. The prob lem of the trans por ta tion due to its
short half-life is solved with the de vel op ment of
99Mo/99mTc gen er a tors. In com bi na tion with its ver sa -
tile chem is try, 99mTc be came far the most im por tant
radionuclide in the di ag nos tics in nu clear med i cine.
The chro mato graphic (n, f)99Mo/99mTc gen er a -
tors are now a days the main source of 99mTc. By elu -
tion, these gen er a tors pro vide large ac tiv i ties of high
qual ity 99mTc. Due to the in her ent dis ad van tages of the
pro duc tion of (n, f)99Mo, at tempts are made to avoid
ura nium fis sion ei ther by us ing (n, g)99Mo or by trans -
fer ring the pro duc tion of 99Mo (or di rectly 99mTc) from 
re ac tors to cy clo trons. Ex trac tion, sub li ma tion, and
gel gen er a tors based on (n, g)99Mo are, de spite some
ad van tages, at the pres ent stage of de vel op ment, not
ca pa ble of re plac ing (n, f)99Mo chro ma tog ra phy. Nu -
clear re ac tions in cy clo trons seem prom is ing but, due
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to the in suf fi cient yields, still can not com pete with
ura nium fis sion.
The chro mato graphic 99Mo/99mTc gen er a tors,
based on the do mes tic tech nol ogy and the im ported
(n, f)99Mo, are rou tinely pro duced in the Vin~a In sti -
tute of Nu clear Sci ences, Lab o ra tory for Ra -
dioisotopes as well.
Tech ne tium-99m finds its use in the form of
99mTc-radiopharmaceuticals. Be side 99mTc-pertechnetate 
ob tained in the gen er a tor eluate, a con sid er able num ber
of these prep a ra tions, de vel oped in the “cold” kit form,
are rou tinely pro duced in the Lab o ra tory.
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PROIZVODWA  I  PRIMENA  TEHNECIJUMA-99m
Za dobijawe 99mTc razvijeno je vi{e tipova generatora, a dominantan je hromatografski u 
kome je 99Mo, dobijen fisijom 235U, sorbovan na Al2O3. Tehnecijum-99m se dobija u obliku
natrijumpertehnetata-99mTc. Me|utim, zbog poznatih nedostataka koje prate dobijawe (n, f)99Mo,
~ine se poku{aji da se izbegne fisija uranijuma. Tehnologije zasnovane na (n, γ)99Mo (sublimacija,
ekstrakcija, gel), sa izuzetkom gel generatora, od ograni~enog su zna~aja. Molibden-99 ili
direktno 99mTc mogu se dobiti kori{}ewem nekih nuklearnih reakcija u ciklotronu ali, za sada,
dobijeni rezultati ne zadovoqavaju. Tehnecijum-99m koristi se u obliku 99mTc-radiofarmaceutika 
koji se dobijaju dodavawem 99mTc-eluata u neaktivni (“hladni”) pribor. Hromatografski (n, f)
99Mo/99mTc gen er a tor i vi{e 99mTc-radiofarmaceutika razvijeno je i redovno se proizvode u
Laboratoriji za radioizotope Instituta za nuklearne nauke “Vin~a”.
Kqu~ne re~i: tehnecijum-99m, molibden-99, tehnecijum-99m gen er a tor, tehnecijum-99m              
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